Current development of COVID-19 diagnostics, vaccines and therapeutics.

Animals Antiviral Agents / therapeutic use Betacoronavirus COVID-19 COVID-19 Vaccines China Clinical Trials as Topic Coronavirus Infections / diagnosis Humans Pandemics / prevention & control Pneumonia, Viral / diagnosis SARS-CoV-2 Viral Vaccines / immunology World Health Organization
Diagnostic approaches SARS-CoV-2 Therapeutics Vaccines

Journal

Microbes and infection
ISSN: 1769-714X
Titre abrégé: Microbes Infect
Pays: France
ID NLM: 100883508

Informations de publication

Date de publication:
Historique:
received: 30 04 2020
accepted: 01 05 2020
pubmed: 11 5 2020
medline: 15 8 2020
entrez: 11 5 2020
Statut: ppublish

Résumé

A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection.

Identifiants

DOI: 10.1016/j.micinf.2020.05.001 PMID: 32387332 PMC: PMC7200352
pubmed: 32387332
pii: S1286-4579(20)30079-4
doi: 10.1016/j.micinf.2020.05.001
pmc: PMC7200352
pii:
doi:

Substances chimiques

Antiviral Agents 0
COVID-19 Vaccines 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-235

Informations de copyright

Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Références

Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Clin Microbiol Infect. 2019 Dec;25(12):1539-1545
pubmed: 31004768
J Clin Med. 2020 Feb 26;9(3):
pubmed: 32110875
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
Sci Transl Med. 2016 Feb 17;8(326):326ra21
pubmed: 26888429
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Nat Commun. 2014;5:3067
pubmed: 24473083
Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antiviral Res. 2016 Sep;133:165-77
pubmed: 27468951
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
N Engl J Med. 2020 Feb 20;382(8):760-762
pubmed: 31978944
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Science. 2020 Feb 21;367(6480):
pubmed: 32079747
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Microbes Infect. 2020 Mar;22(2):74-79
pubmed: 32017984
Curr Trop Med Rep. 2020 Mar 3;:1-4
pubmed: 32219057
Sci Adv. 2019 Apr 10;5(4):eaav4580
pubmed: 30989115
Expert Opin Ther Targets. 2017 Feb;21(2):131-143
pubmed: 27936982
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Monaldi Arch Chest Dis. 2020 Mar 30;90(1):
pubmed: 32231348
Nature. 2020 Mar;579(7799):321
pubmed: 32179860
Lancet. 2004 Mar 20;363(9413):938-47
pubmed: 15043961
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Lancet. 2020 Mar 21;395(10228):949
pubmed: 32087125
Int J Antimicrob Agents. 2020 May;55(5):105955
pubmed: 32234468
Nat Commun. 2016 Nov 22;7:13473
pubmed: 27874853
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466
Cell Mol Immunol. 2020 Jul;17(7):765-767
pubmed: 32047258
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Front Microbiol. 2020 Feb 28;11:298
pubmed: 32265848

Auteurs

Naru Zhang (N)

Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.

Chaoqun Li (C)

Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.

Yue Hu (Y)

Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.

Kangchen Li (K)

Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.

Jintian Liang (J)

Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.

Lili Wang (L)

Research Center of Chinese Jujube, Hebei Agriculture University, Baoding, China.

Lanying Du (L)

Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA. Electronic address: ldu@nybc.org.

Shibo Jiang (S)

Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China. Electronic address: shibojiang@fudan.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Régions géographiques › Asie › Extrême-Orient › Chine › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Nidovirales › Infections à Coronaviridae › Infections à coronavirus › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Current development of COVID-19 diagnostics,...
questionsmedicales.fr › Organisations et économie des soins de santé › Organismes › Agences internationales › Nations Unies › Organisation mondiale de la santé › Current development of COVID-19 diagnostics,...